

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 503)

**CHANGE OF COMPANY SECRETARY AND
AUTHORISED REPRESENTATIVE**

The Board announces that with effect from 13 June 2019:

- (1) Mr. Yiu resigned as the Company Secretary and the Authorised Representative; and
- (2) Mr. Pang has been appointed as the Company Secretary and the Authorised Representative.

The board of directors (the “**Board**”) of Lansens Pharmaceutical Holdings Limited (the “**Company**”) announces that Mr. Yiu Chi Hung (“**Mr. Yiu**”) has tendered his resignation as the company secretary (the “**Company Secretary**”) of the Company and one of the authorised representatives (the “**Authorised Representatives**”, each “**Authorised Representative**”), for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance (Cap. 622 of the Laws of Hong Kong), with effect from 13 June 2019, due to the change in Mr. Yiu’s role and job duties assigned. Mr. Yiu confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that Mr. Pang Kai Fai (“**Mr. Pang**”), the finance manager of the Company, has been appointed as the Company Secretary and the Authorised Representative, with effect from 13 June 2019. Mr. Pang has over eight years of experience in auditing, finance and accounting. Mr. Pang holds a bachelor degree in accounting for management from Aston University in the United Kingdom, and is a member of Hong Kong Institute of Certified Public Accountants.

By Order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 12 June 2019

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Lee Jin Yi, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.